AUROPHARMA — Aurobindo Pharma Share News
0.000.00%
Last trade - 00:00- IN₹904.32bn
- IN₹877.78bn
- IN₹336.53bn
Brief: Aurobindo Pharma Says US FDA Classifies Eugia Pharma Unit-II As 'Official Action Indicated'
Brief: Aurobindo Pharma Gets Tax Demand And Penalty Of 776.1 Million Rupees Each
Brief: Aurobindo Pharma Says US FDA Inspects Unit-IV Of APL Healthcare
Brief: Aurobindo Pharma Says Eugia Pharma Launches Pomalidomide Capsules In US
Brief: Aurobindo Pharma Says Completion Of USFDA Inspection At Unit I Of Eugia Pharma Specialities
Brief: Aurobindo Pharma Says Eugia Pharma Receives USFDA Approval For Everolimus Tablets
Brief: Aurobindo Pharma Says Tax Department Demands Recovery Of Refunds From Co
India's Aurobindo Pharma dermatitis drug could become $300 million brand, says HSBC
Brief: Aurobindo Pharma Says FDA Approves Adquey For Atopic Dermatitis
India's Aurobindo Pharma hits over three-month low; US business still weak, Citi says
Brief: Aurobindo Pharma Q3 Consol Net PAT 9.1 Billion Rupees
Brief: Aurobindo Pharma Records One-Time Charge Of 653.3 Million Rupees In Q3 Due To New Labour Codes
India's Aurobindo Pharma posts higher profit on steady domestic demand
Brief: Aurobindo Pharma Says US FDA Inspected Unit-III Of Eugia Pharma
India's Aurobindo Pharma jumps after Citi says penicillin-G import price floor removes uncertainty
Brief: Aurobindo Pharma Says Subsidiary Incorporated A New Wholly Owned Subsidiary In Philippines
Generic Advair nod helps India's Aurobindo Pharma, raises competition for Cipla, Citi says
Brief: Aurobindo Pharma Curateq Receives NOC From Canada Health Authority For Biosimilar Dyrupeg
Brief: Aurobindo Pharma To Buy Non-Oncology Prescription Formulations Business Of Khandelwal Laboratories